HK1181398A1 - Binding members for human cytomegalovirus - Google Patents
Binding members for human cytomegalovirusInfo
- Publication number
- HK1181398A1 HK1181398A1 HK13108568.0A HK13108568A HK1181398A1 HK 1181398 A1 HK1181398 A1 HK 1181398A1 HK 13108568 A HK13108568 A HK 13108568A HK 1181398 A1 HK1181398 A1 HK 1181398A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- binding members
- human cytomegalovirus
- cytomegalovirus
- human
- binding
- Prior art date
Links
- 241000701024 Human betaherpesvirus 5 Species 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/088—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/089—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Radiology & Medical Imaging (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- AIDS & HIV (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28983509P | 2009-12-23 | 2009-12-23 | |
EP09015951 | 2009-12-23 | ||
US32005710P | 2010-04-01 | 2010-04-01 | |
EP10003669 | 2010-04-01 | ||
PCT/EP2010/070568 WO2011076883A1 (en) | 2009-12-23 | 2010-12-22 | Binding members for human cytomegalovirus |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1181398A1 true HK1181398A1 (en) | 2013-11-08 |
Family
ID=44246877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK13108568.0A HK1181398A1 (en) | 2009-12-23 | 2013-07-22 | Binding members for human cytomegalovirus |
Country Status (17)
Country | Link |
---|---|
US (1) | US9346874B2 (xx) |
EP (1) | EP2516463B1 (xx) |
JP (1) | JP5833565B2 (xx) |
KR (1) | KR20120105543A (xx) |
CN (1) | CN102892782B (xx) |
AU (1) | AU2010334809C1 (xx) |
BR (1) | BR112012015523A2 (xx) |
CA (1) | CA2785587A1 (xx) |
CO (1) | CO6640284A2 (xx) |
EA (1) | EA201270662A1 (xx) |
HK (1) | HK1181398A1 (xx) |
IL (1) | IL220617A0 (xx) |
MX (1) | MX2012007489A (xx) |
NZ (1) | NZ600974A (xx) |
SG (1) | SG181901A1 (xx) |
WO (1) | WO2011076883A1 (xx) |
ZA (1) | ZA201204513B (xx) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2772265B1 (en) | 2010-05-14 | 2018-01-17 | Oregon Health & Science University | Recombinant HCMV and RHCMV vectors and uses thereof |
RS57397B8 (sr) | 2011-06-10 | 2020-01-31 | Univ Oregon Health & Science | Cmv glikoproteini i rekombinantni vektori |
CN104334583A (zh) * | 2012-03-28 | 2015-02-04 | 弗·哈夫曼-拉罗切有限公司 | 抗-hcmv特应抗体及其用途 |
US20150110794A1 (en) * | 2012-04-30 | 2015-04-23 | Cell Signaling Technology, Inc. | Anti-Human Cytomegalovirus Antibodies And Use Thereof |
SI2964769T1 (sl) * | 2013-03-05 | 2018-12-31 | Oregon Health & Sccience University | Citomegalovirusni vektorji, ki omogočajo krmiljenje ciljanja T-celic |
US20150152166A1 (en) * | 2013-04-19 | 2015-06-04 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of cytomegalovirus |
RU2015155601A (ru) * | 2013-06-10 | 2017-07-14 | Мерк Шарп И Доум Корп. | Нейтрализующие цитомегаловирус (цмв) антигенсвязывающие белки |
KR101996427B1 (ko) | 2014-07-16 | 2019-07-04 | 오레곤 헬스 앤드 사이언스 유니버시티 | 외인성 항원을 포함하는 인간 시토메갈로바이러스 |
JP6816031B2 (ja) | 2015-02-10 | 2021-01-20 | オレゴン ヘルス アンド サイエンス ユニバーシティ | 非標準的なcd8+t細胞応答を生成するのに有用な方法および組成物 |
JP7133468B2 (ja) | 2015-11-20 | 2022-09-08 | オレゴン・ヘルス・アンド・サイエンス・ユニバーシティ | マイクロrna認識エレメントを含むcmvベクター |
US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
PE20190840A1 (es) | 2016-10-18 | 2019-06-17 | Univ Oregon Health & Science | Vectores de citomegalovirus que provocan celulas t restringidas por moleculas del complejo mayor de histocompatibilidad e |
MA53158A (fr) * | 2018-07-20 | 2021-05-26 | Aicuris Gmbh & Co Kg | Procédés de criblage et d'identification d'agents inhibant ou modulant le complexe de sortie nucléaire du virus de l'herpès |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
CN112898414B (zh) * | 2019-12-04 | 2024-05-10 | 珠海泰诺麦博制药股份有限公司 | 抗人巨细胞病毒抗体及其用途 |
US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
GB202020135D0 (en) * | 2020-12-18 | 2021-02-03 | Ucl Business Ltd | Immunogenic peptide |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
US4424200A (en) | 1979-05-14 | 1984-01-03 | Nuc Med Inc. | Method for radiolabeling proteins with technetium-99m |
US4479930A (en) | 1982-07-26 | 1984-10-30 | Trustees Of The University Of Massachusetts | Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
FR2543570B1 (fr) | 1983-03-31 | 1985-08-09 | Pasteur Institut | Anticorps monoclonaux anticytomegalovirus humains, hybridomes secreteurs de ces anticorps et polypeptides porteurs d'un determinant antigenique sequentiel de cytomegalovirus humains |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8404368D0 (en) | 1984-02-20 | 1984-03-28 | Cogent Ltd | Monoclonal antibodies to human cytomegalovirus |
US5171568A (en) | 1984-04-06 | 1992-12-15 | Chiron Corporation | Recombinant herpes simplex gb-gd vaccine |
US6100064A (en) | 1984-04-06 | 2000-08-08 | Chiron Corporation | Secreted viral proteins useful for vaccines and diagnostics |
US5244792A (en) | 1984-04-06 | 1993-09-14 | Chiron Corporation | Expression of recombinant glyoprotein B from herpes simplex virus |
US4618578A (en) | 1984-07-17 | 1986-10-21 | Chiron Corporation | Expression of glycoprotein D of herpes simplex virus |
FR2563630B1 (fr) | 1984-04-27 | 1988-02-19 | Pasteur Institut | Anticorps monoclonaux anticytomegalovirus et procedes pour le diagnostic in vitro des infections par les cytomegalovirus humains et d'une proteine-kinase inductible par les cytomegalovirus et susceptible d'etre reconnue par les susdits anticorps monoclonaux |
US5612041A (en) | 1984-07-17 | 1997-03-18 | Chiron Corporation | Recombinant herpes simplex gD vaccine |
US5194256A (en) | 1984-08-21 | 1993-03-16 | The Board Of Trustees Of The Leland Sanford Junior University | Purified human cytomegalovirus protein |
US4743562A (en) | 1984-08-21 | 1988-05-10 | The Board Of Trustees Of The Leland Stanford Junior University | Purified human cytomegalovirus protein |
WO1986002092A1 (en) | 1984-09-28 | 1986-04-10 | Teijin Limited | Mouse human hybridoma producing antivirus human antibody, process for its preparation, and antivirus human monoclonal antibody |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
KR910000736B1 (ko) | 1985-12-06 | 1991-02-06 | 데이진 가부시키가이샤 | 사이토메갈로 바이러스에 대한 사람·모노클로날 항체와 그 제조방법 |
US6162620A (en) | 1986-03-07 | 2000-12-19 | Cogent Limited | Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
DE3782867D1 (en) | 1986-06-12 | 1993-01-14 | Behringwerke Ag, 3550 Marburg, De | Human cytomegalovirus phospho-protein |
US5248768A (en) | 1986-11-24 | 1993-09-28 | The Children's Hospital, Incorporated | Immunogenic glycoproteins of human cytomegalovirus |
US5124440A (en) | 1986-11-24 | 1992-06-23 | The Childrens Hospital, Inc. | Antibody and T cell recognition sites on glycoproteins comprising the GCI complex of human cytomegalovirus |
US5126130A (en) | 1986-11-24 | 1992-06-30 | The Childrens Hospital Incorporated | Monoclonal antibodies reactive with specific antigenic sites on human cytomegalovirus glycoprotein a |
US5153311A (en) | 1986-11-24 | 1992-10-06 | The Children's Hospital, Incorporated | Immunogenic glycoproteins of human cytomegalovirus gCII |
LU86752A1 (fr) | 1987-01-30 | 1988-08-23 | Univ Bruxelles | Procede de production d'anticorps monoclonaux humains(igg)anticytomegalovirus et anticorps monoclonaux ainsi obtenus |
GB8729251D0 (en) | 1987-12-15 | 1988-01-27 | Cogent Ltd | Human cytomegalovirus protein |
DE68929478T2 (de) | 1988-01-29 | 2004-04-29 | Aventis Pasteur | Rekombinante CMV-Neutralisierungsproteine |
US5547834A (en) | 1988-01-29 | 1996-08-20 | Chiron Corporation | Recombinant CMV neutralizing proteins |
US6733989B1 (en) | 1988-02-24 | 2004-05-11 | Dade Behring Marburg Gmbh | Structural phosphoprotein (pp28) of human cytomegalovirus (HCMV), the preparation and use thereof |
EP0413738A1 (en) | 1988-05-09 | 1991-02-27 | The Children's Hospital, Incorporated | Vectors encoding hcmv glycoprotein and expression products |
US5185243A (en) | 1988-08-25 | 1993-02-09 | Syntex (U.S.A.) Inc. | Method for detection of specific nucleic acid sequences |
AU4664689A (en) | 1988-12-12 | 1990-07-10 | Children's Hospital Incorporated, The | Proteolytic fragments obtained from human cytomegalovirus glycoprotein complex i |
US5180813A (en) | 1989-03-24 | 1993-01-19 | University Of Iowa Research Foundation | Early envelope glycoprotein of human cytomegalovirus (hmcv) and monoclonal antibodies to the glycoproteins |
WO1991002004A1 (en) | 1989-08-07 | 1991-02-21 | Children's Biomedical Research Center | IMMUNOGENIC GLYCOPROTEINS OF HUMAN CYTOMEGALOVIRUS gCII |
WO1991004277A1 (en) | 1989-09-14 | 1991-04-04 | Children's Biomedical Research Institute | Monoclonal antibodies specific to cytomegalovirus glycoprotein |
WO1991005876A1 (en) | 1989-10-20 | 1991-05-02 | Children's Biomedical Research Institute | Human cytomegalovirus-specific monoclonal antibody cocktail |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
GB9008223D0 (en) | 1990-04-11 | 1990-06-13 | Royal Free Hosp School Med | Improvements relating to the detection of viruses |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
JP2535455B2 (ja) | 1991-02-07 | 1996-09-18 | 帝人株式会社 | サイトメガロウイルスに対するヒト・モノクロ―ナル抗体を産生するハイブリド―マ |
JPH053794A (ja) | 1991-06-26 | 1993-01-14 | Green Cross Corp:The | 抗サイトメガロウイルスヒトモノクローナル抗体およびその産生細胞 |
US5744298A (en) | 1991-08-29 | 1998-04-28 | Behringwerke Aktiengesellschaft | DNA sequences which encode immunoreactive HCMV-specific peptides |
JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
SE9201281L (sv) | 1992-04-23 | 1993-10-24 | Bioinvent Int Ab | Nya humana monoklonala antikroppar och förfarande för framställning därav |
JPH05260961A (ja) | 1992-05-21 | 1993-10-12 | Teijin Ltd | サイトメガロウイルスに対するヒト・モノクローナル抗体を産生するハイブリドーマ |
GB9221654D0 (en) | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant human anti-cytomegalovirus antibodies |
JPH06157349A (ja) | 1992-11-13 | 1994-06-03 | Teijin Ltd | サイトメガロウイルス感染症治療剤 |
ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
US5750106A (en) | 1993-01-28 | 1998-05-12 | Novartis Ag | Human monoclonal antibodies to cytomegalovirus |
AU6777594A (en) | 1993-04-30 | 1994-11-21 | Scripps Research Institute, The | Human monoclonal antibodies to human cytomegalovirus, and methods therefor |
JP2538536B2 (ja) | 1994-07-06 | 1996-09-25 | 帝人株式会社 | サイトメガロウイルスに対するヒト・モノクロ―ナル抗体を産生するハイブリド―マ |
JP2538537B2 (ja) | 1994-07-06 | 1996-09-25 | 帝人株式会社 | サイトメガロウイルスに対するヒト・モノクロ―ナル抗体 |
JPH0859508A (ja) | 1994-08-16 | 1996-03-05 | Teijin Ltd | サイトメガロウイルス網膜炎予防または治療剤 |
JPH0859509A (ja) | 1994-08-16 | 1996-03-05 | Teijin Ltd | サイトメガロウイルス抗原血症治療剤およびサイトメガロウイルス感染症治療剤 |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5783383A (en) | 1995-05-23 | 1998-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method of detecting cytomegalovirus (CMV) |
US20020102562A1 (en) | 1995-05-24 | 2002-08-01 | Pasteur Merieux Serums Et Vaccines S.A. | Recombinant CMV neutralizing proteins |
US5800981A (en) | 1996-02-22 | 1998-09-01 | University Of Limburg | Human cytomegalovirus antigen and its use |
US5814468A (en) | 1996-03-27 | 1998-09-29 | Coulter International Corp. | Methods of enumerating receptor molecules for specific binding partners on formed bodies and in solution |
AU728285C (en) | 1996-08-14 | 2002-02-21 | Wistar Institute Of Anatomy And Biology, The | Methods and compositions for preventing or retarding the development of atherosclerotic lesions |
US6183752B1 (en) | 1997-02-05 | 2001-02-06 | Pasteur Merieux Serums Et Vaccins | Restenosis/atherosclerosis diagnosis, prophylaxis and therapy |
DE19756214C1 (de) | 1997-12-17 | 1999-02-25 | Biotest Ag | Polypeptide mit Aminosäuresequenzen aus dem N-terminalen Bereich von gp116 und deren Verwendung bei der Diagnostik, Prophylaxe und Therapie |
DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
WO2000034784A1 (en) | 1998-12-10 | 2000-06-15 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6569616B1 (en) | 1999-07-29 | 2003-05-27 | Wisconsin Alumni Research Foundation | Human cytomegalovirus glycoprotein O as a new drug target and subunit vaccine candidate |
CA2420944A1 (en) | 2000-08-30 | 2002-03-07 | Chemocentryx, Inc. | Inhibition of cmv infection and dissemination |
ATE488583T1 (de) | 2001-02-21 | 2010-12-15 | Wistar Inst | Rekombinant vektor, der ein infektiöses humanes cytomegalovirus genom mit konserviertem wildtyp- charakteristika klinisher isolate enthält |
EP1539233B1 (en) | 2001-07-12 | 2011-04-27 | FOOTE, Jefferson | Super humanized antibodies |
US20030157108A1 (en) | 2001-10-25 | 2003-08-21 | Genentech, Inc. | Glycoprotein compositions |
NZ534205A (en) | 2001-12-22 | 2006-04-28 | Antibody A 4 | Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins |
WO2004076677A2 (en) | 2003-02-26 | 2004-09-10 | Institute For Research In Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
GB2398783A (en) | 2003-02-26 | 2004-09-01 | Antonio Lanzavecchia | A method for producing immortalised human B memory lymphocytes |
US20040228842A1 (en) | 2003-02-27 | 2004-11-18 | Shan Lu | Compositions and methods for cytomegalovirus treatment |
CA2527694C (en) | 2003-05-30 | 2015-07-14 | Hendricus Renerus Jacobus Mattheus Hoogenboom | Fab library for the preparation of anti vegf and anti rabies virus fabs |
WO2006056027A1 (en) | 2004-11-29 | 2006-06-01 | The Council Of The Queensland Institute Of Medical Research | Human cytomegalovirus immunotherapy |
AU2006325236B2 (en) | 2005-12-16 | 2011-11-10 | Ribovax Biotechnologies Sa | Methods for obtaining immortalized antibody secreting cells |
WO2007094423A1 (ja) | 2006-02-15 | 2007-08-23 | Evec Incorporated | ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
JP5822433B2 (ja) | 2006-06-07 | 2015-11-24 | ザ・トラスティーズ・オブ・プリンストン・ユニバーシティThe Trustees Of Princeton University | ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体 |
GB0612944D0 (en) * | 2006-06-29 | 2006-08-09 | Bhr Group Ltd | Water jet cutting apparatus |
US8153129B2 (en) | 2006-12-15 | 2012-04-10 | Ribovax Biotechnologies S.A. | Antibodies against human cytimegalovirus (HCMV) |
GB0700133D0 (en) | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
US7947274B2 (en) | 2007-01-04 | 2011-05-24 | Humabs, LLC. | Human cytomegalovirus neutralising antibodies and use thereof |
CN101605808A (zh) | 2007-02-07 | 2009-12-16 | 希格马托制药工业公司 | 人巨细胞病毒(hcmv)的重组抗原 |
US20100158927A1 (en) | 2007-03-29 | 2010-06-24 | Technion Research & Development Foundation Ltd. | Antibodies, methods and kits for diagnosing and treating melanoma |
US8361473B2 (en) | 2007-03-29 | 2013-01-29 | Technion Research & Development Foundation Ltd. | Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases |
EP2173771A1 (en) | 2007-07-04 | 2010-04-14 | Ribovax Biotechnologies SA | Antibodies against human cytomegalovirus (hcmv) |
EP2190876A1 (en) | 2007-08-22 | 2010-06-02 | Ribovax Biotechnologies SA | Antibodies against human cytomegalovirus (hcmv) |
WO2009085383A1 (en) | 2007-12-19 | 2009-07-09 | Dcb-Usa Llc | Anti-human cytomegalovirus antibodies |
WO2009114560A2 (en) | 2008-03-10 | 2009-09-17 | Spaltudaq Corporation | Compositions and methods for the therapy and diagnosis of cytomegalovirus |
PE20141398A1 (es) | 2008-07-16 | 2014-10-18 | Inst Research In Biomedicine | Anticuerpos neutralizantes de citomegalovirus humano |
KR20140041951A (ko) | 2008-07-16 | 2014-04-04 | 인스티튜트 포 리서치 인 바이오메드슨 | 인간 사이토메갈바이러스 중화 항체 및 이의 용도 |
MX2011010382A (es) | 2009-04-01 | 2012-01-12 | Evec Inc | Anticuerpo monoclonal capaz de unirse a epitopo discontinuo especifico que ocurre en la region ad1 de la glicoproteina gb de citomegalovirus humano y fragmento de union a antigeno del mismo. |
KR101900435B1 (ko) | 2010-06-16 | 2018-09-20 | 트렐리스 바이오싸이언스 인코포레이티드 | 인간 사이토메갈로바이러스 gB 단백질에 대한 고친화도 인간 항체 |
-
2010
- 2010-12-22 EP EP10796400.9A patent/EP2516463B1/en not_active Not-in-force
- 2010-12-22 KR KR20127019531A patent/KR20120105543A/ko not_active Application Discontinuation
- 2010-12-22 CN CN201080064592.3A patent/CN102892782B/zh not_active Expired - Fee Related
- 2010-12-22 EA EA201270662A patent/EA201270662A1/ru unknown
- 2010-12-22 CA CA 2785587 patent/CA2785587A1/en not_active Abandoned
- 2010-12-22 JP JP2012545334A patent/JP5833565B2/ja not_active Expired - Fee Related
- 2010-12-22 AU AU2010334809A patent/AU2010334809C1/en not_active Ceased
- 2010-12-22 WO PCT/EP2010/070568 patent/WO2011076883A1/en active Application Filing
- 2010-12-22 MX MX2012007489A patent/MX2012007489A/es not_active Application Discontinuation
- 2010-12-22 NZ NZ60097410A patent/NZ600974A/en not_active IP Right Cessation
- 2010-12-22 BR BR112012015523A patent/BR112012015523A2/pt not_active IP Right Cessation
- 2010-12-22 SG SG2012046686A patent/SG181901A1/en unknown
-
2012
- 2012-06-19 ZA ZA2012/04513A patent/ZA201204513B/en unknown
- 2012-06-22 US US13/530,891 patent/US9346874B2/en not_active Expired - Fee Related
- 2012-06-24 IL IL220617A patent/IL220617A0/en unknown
- 2012-07-23 CO CO12122672A patent/CO6640284A2/es not_active Application Discontinuation
-
2013
- 2013-07-22 HK HK13108568.0A patent/HK1181398A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20120105543A (ko) | 2012-09-25 |
CA2785587A1 (en) | 2011-06-30 |
AU2010334809C1 (en) | 2015-02-26 |
US9346874B2 (en) | 2016-05-24 |
NZ600974A (en) | 2014-08-29 |
ZA201204513B (en) | 2013-02-27 |
CN102892782B (zh) | 2015-01-14 |
US20130089559A1 (en) | 2013-04-11 |
IL220617A0 (en) | 2012-08-30 |
AU2010334809A1 (en) | 2012-07-26 |
EA201270662A1 (ru) | 2013-01-30 |
JP5833565B2 (ja) | 2015-12-16 |
MX2012007489A (es) | 2012-11-29 |
SG181901A1 (en) | 2012-08-30 |
EP2516463B1 (en) | 2016-06-15 |
JP2013515469A (ja) | 2013-05-09 |
WO2011076883A1 (en) | 2011-06-30 |
AU2010334809B2 (en) | 2014-10-23 |
EP2516463A1 (en) | 2012-10-31 |
CO6640284A2 (es) | 2013-03-22 |
BR112012015523A2 (pt) | 2017-04-18 |
CN102892782A (zh) | 2013-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1181398A1 (en) | Binding members for human cytomegalovirus | |
ZA201204502B (en) | Prosthesis | |
IL225397A0 (en) | Antibodies bind human collagen ii | |
GB201003573D0 (en) | Hand prothesis | |
GB0900269D0 (en) | Silicate-substituted hydroxyapatite | |
ZA201109212B (en) | Prosthesis | |
ZA201208994B (en) | Prosthesis | |
GB2474735B (en) | Front-depression stapling device | |
PL2278285T3 (pl) | Dołączany odbiornik obciążenia | |
EP2486890A4 (en) | SUPPORT FOR AN IMPLANT | |
GB2476226B (en) | Optimisation | |
IL218863A (en) | Device for dynamic unloading of vertebrae | |
SG10201503080XA (en) | Eif4e binding peptides | |
GB2469367B (en) | Bookbinding device | |
GB2486140B (en) | Weightlifting aid | |
AU331093S (en) | Toaster | |
GB0900576D0 (en) | Toaster | |
GB0914067D0 (en) | Filter means | |
GB0903876D0 (en) | Spine Safe | |
TWM400980U (en) | Binding | |
GB0913794D0 (en) | Binding surfaces | |
HU0900041D0 (en) | Crinoline | |
GB201003906D0 (en) | Binding polypeptides | |
GB0904217D0 (en) | Binding polypeptides | |
GB0921199D0 (en) | Prosthesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20191224 |